# A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

> **NCT05256472** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 70 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- First-line Treatment

## Interventions

- **DRUG:** AK104
- **DRUG:** axitinib

## Key facts

- **NCT ID:** NCT05256472
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-22
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256472, "A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05256472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*